首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

歐洲T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體瘤）

市場調查報告書

商品編碼

1452627

歐洲T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體瘤）

Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 78 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年歐洲T細胞治療市值為6.9924億美元，預計2030年將達到23.4549億美元；預計2022年至2030年CAGR為16.3%。

T 細胞治療批准數量的增加推動了歐洲 T 細胞治療市場

標靶治療、更快、更有效的恢復以及減少副作用都是 T 細胞療法的優點。在全球範圍內，由於獲得了各種批准，細胞療法被廣泛採用。例如，

2023 年：歐盟委員會批准了 Breyanzi（lisocabtagene maraleucel；liso-cel），這是一種針對 CD19 的嵌合抗原受體 (CAR) T 細胞療法。 CAR T 細胞療法中發現的 4-1BB 共刺激結構域可增強 CAR T 細胞的擴增和持久性。第一線化療難治的高級別B 細胞淋巴瘤(HGBCL)、瀰漫性大B 細胞淋巴瘤(DLBCL)、原發性縱隔大B 細胞淋巴瘤(PMBCL) 和3B 級濾泡性淋巴瘤(FL3B) 的成人或完成治療後一年內復發的人有資格接受這種治療。

2022 年：經歐洲人用醫藥產品委員會 (CHMP) 批准，Atara Biotherapeutics 的 Ebvallo 將成為世界上第一個獲得許可的同種異體 T 細胞療法。

2022年：吉利德公司旗下Kite宣布Yescarta（axicabtagene ciloleucel）已獲得歐盟委員會批准用於治療成人高級別B細胞淋巴瘤（HGBL）和瀰漫性大B細胞淋巴瘤（DLBCL）對一線化療抗藥性或完成化療後一年內復發的人。

因此，越來越多的 T 細胞療法獲批正在推動市場成長。

歐洲T細胞治療市場概況

歐洲 T 細胞治療市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。德國和英國等國家預計將成為該地區市場的最大貢獻者。血液系統惡性腫瘤和實體腫瘤盛行率的上升以及隨後 T 細胞療法批准的增加是推動歐洲市場成長的主要因素。

根據英國國家醫療服務體系 (NHS) 的數據，英國每年約有 800 人被診斷出患有急性淋巴性白血病，英國每年約有 5,500 人被診斷出患有 B 細胞淋巴瘤。由於英國白血病和淋巴瘤的流行，人們選擇 T 細胞療法來治療這些癌症。由於 T 細胞療法的知名度和積極成果，NHS 已與阿斯特捷利康等多家公司達成協議，以擴大個人化 CAR T 細胞療法的使用範圍。

歐洲 T 細胞治療市場收入及 2030 年預測（百萬美元）

歐洲T細胞治療市場細分

歐洲 T 細胞治療市場分為模式、治療類型、適應症和國家。

根據模式，歐洲 T 細胞治療市場分為研究和商業化。 2022年，商業化細分市場將佔據更大的市場佔有率。

根據治療類型，歐洲T細胞治療市場分為CAR T細胞療法和T細胞受體（TCR）療法。 2022年，CAR T細胞療法領域將佔據更大的市場佔有率。

根據適應症，歐洲 T 細胞治療市場分為血液惡性腫瘤和實體腫瘤。 2022 年，血液惡性腫瘤細分市場佔據最大市場。

根據國家/地區，歐洲 T 細胞治療市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。 2022 年，德國在歐洲 T 細胞治療市場佔據主導地位。

百時美施貴寶公司、吉利德科學公司、Immunocore Holdings Plc、信達生物製品公司、楊森全球服務有限責任公司、傳奇生物科技公司和諾華公司是歐洲 T 細胞治療市場上的一些領先公司。

In 2023: The European Commission has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. A 4-1BB costimulatory domain found in CAR T-cell therapy augments the expansion and persistence of CAR T cells. Adults with high grade B-cell lymphoma (HGBCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) who are refractory to first-line chemotherapy or who relapsed within a year of finishing treatment are eligible for this treatment.

In 2022: With approval from the European Committee for Medicinal Products for Human Use (CHMP), Ebvallo from Atara Biotherapeutics is set to become the world's first licensed allogeneic T-cell therapy.

In 2022: Kite, a Gilead Company, announced that Yescarta (axicabtagene ciloleucel) has been approved by the European Commission for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) who are refractory to first-line chemotherapy or who relapse within a year of finishing it.

Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.

Europe T Cell Therapy Market Overview

The European T-cell therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of hematologic malignancies and solid tumors and the subsequent rise in approval of T-cell therapy are the major factors driving the market growth in Europe.

According to National Health Service (NHS), ~800 people in the UK are diagnosed with acute lymphoblastic leukemia yearly, and ~ 5,500 people in England are diagnosed with B-cell lymphoma annually. Due to the prevalence of leukemia and lymphoma in the UK, people opt for T-cell therapy to treat these cancers. Owing to the awareness and positive results of T-cell therapies, NHS has struck deals with various companies, such as AstraZeneca, to expand access to personalized CAR T-cell therapies.

Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Europe T Cell Therapy Market Segmentation

The Europe T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Europe T cell therapy market is segmented into Germany, UK, France, Italy, Spain, the Rest of Europe. Germany dominated the Europe T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Europe T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Europe T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - Europe Market Analysis

5.1 Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

8.1 Overview
8.2 Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 Europe T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe T Cell Therapy Market - Country Analysis

9.1 Europe

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Immunocore Holdings Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Legend Biotech Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Janssen Global Services LLC
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Gilead Sciences Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Bristol-Myers Squibb Co
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Novartis AG
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Europe T Cell Therapy Market Segmentation
Table 2. Europe T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. UK Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. UK Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. UK Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. France: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 12. France: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. France: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 14. France: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 17. Italy: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 22. Spain: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 25. Rest of Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 26. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 27. Recent Organic Growth Strategies in Europe T Cell Therapy Market
Table 28. Recent Inorganic Growth Strategies in the Europe T Cell Therapy Market
Table 29. Glossary of Terms, Europe T Cell Therapy Market

List Of Figures

Figure 1. Europe T Cell Therapy Market Segmentation, By Country
Figure 2. Europe T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 15. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. UK Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Germany: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. France: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Italy: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Spain: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Growth Strategies in T Cell Therapy Market